Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models

Daily vs. weekly dosing with EGFR inhibitors (gefitinib and lapatinib) and an AKT inhibitor (MK2206) were compared in two rodent breast cancer models. Female Sprague-Dawley rats were administered methylnitrosourea (MNU) at 50 days of age, and gefitinib (daily/weekly dosing at 10/70 mg/kg BW) or lapa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Rep
Hlavní autoři: Lubet, Ronald A., Steele, Vernon E., Juliana, M.M., Bode, Ann, Moeinpour, Fariba, Grubbs, Clinton J.
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2018
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6072405/
https://ncbi.nlm.nih.gov/pubmed/29565450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2018.6313
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky